[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Shukla et al., 2013 - Google Patents

Site-Specific Ocular Nucleic Acid Delivery

Shukla et al., 2013

Document ID
2811553816083577041
Author
Shukla R
Cheng K
Publication year
Publication venue
Focal Controlled Drug Delivery

External Links

Snippet

The eye is a very complex organ consisting of many anterior and posterior tissues. Studies over the last 2 decades have demonstrated the promise of using nucleic acids, such as DNA, siRNA, antisense oligonucleotide (AS-ODNs), and aptamer, in treating acquired as …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nuclic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nuclic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Bordet et al. Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives
Botto et al. Early and late stage gene therapy interventions for inherited retinal degenerations
Drag et al. Gene therapy for retinal degenerative diseases: progress, challenges, and future directions
Solinís et al. Treatment of ocular disorders by gene therapy
Cai et al. Nanoparticle applications in ocular gene therapy
Bloquel et al. Non-viral ocular gene therapy: potential ocular therapeutic avenues
Andrieu-Soler et al. Ocular gene therapy: a review of nonviral strategies
Tawfik et al. Nanomedicine and drug delivery to the retina: Current status and implications for gene therapy
Thakur et al. Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers
Issa et al. Non‐viral retinal gene therapy: a review
Wan et al. Gene therapy for ocular diseases meditated by ultrasound and microbubbles
Naik et al. Gene delivery to the retina: focus on non-viral approaches
Kaur et al. Modified mRNA as a Therapeutic Tool for the Heart
Naik et al. Small interfering RNAs (siRNAs) based gene silencing strategies for the treatment of glaucoma: Recent advancements and future perspectives
Manfredi et al. Combined rod and cone transduction by adeno-associated virus 2/8
Hakim et al. Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: Progress towards non-viral systems
Kansara et al. Suprachoroidally delivered DNA nanoparticles transfect retina and retinal pigment epithelium/choroid in rabbits
JP7371083B2 (en) Intraocular delivery of gene therapy expression vectors
Lohia et al. Delivery strategies for CRISPR/Cas genome editing tool for retinal dystrophies: challenges and opportunities
Elbadawy et al. Targeting herpetic keratitis by gene therapy
Saraiva et al. Synthetic nanocarriers for the delivery of polynucleotides to the eye
US20240293334A1 (en) Nonviral gene transfer to the suprachoroidal space
Hao et al. Gene delivery to cornea
Crane et al. Gene therapy to the retina and the cochlea
Lee et al. Anti-VEGF polysiRNA polyplex for the treatment of choroidal neovascularization